Cross Country Healthcare, Inc. (NASDAQ:CCRN) CEO Acquires $66,640.00 in Stock

Share on StockTwits

Cross Country Healthcare, Inc. (NASDAQ:CCRN) CEO Kevin Cronin Clark purchased 8,330 shares of the stock in a transaction dated Friday, June 14th. The stock was acquired at an average price of $8.00 per share, for a total transaction of $66,640.00. Following the completion of the transaction, the chief executive officer now directly owns 250,734 shares of the company’s stock, valued at $2,005,872. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Shares of CCRN stock traded up $0.38 during mid-day trading on Monday, reaching $8.43. The company’s stock had a trading volume of 7,472 shares, compared to its average volume of 142,192. The firm’s 50 day moving average is $7.55. Cross Country Healthcare, Inc. has a 12-month low of $6.75 and a 12-month high of $12.75. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.08 and a quick ratio of 2.08. The stock has a market cap of $301.09 million, a price-to-earnings ratio of 70.17, a PEG ratio of 11.61 and a beta of 1.05.

Cross Country Healthcare (NASDAQ:CCRN) last issued its earnings results on Wednesday, May 1st. The business services provider reported $0.02 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.06. Cross Country Healthcare had a negative net margin of 2.54% and a positive return on equity of 1.19%. The business had revenue of $195.10 million for the quarter, compared to the consensus estimate of $198.47 million. During the same quarter last year, the firm posted $0.06 EPS. The business’s revenue for the quarter was down 7.2% compared to the same quarter last year. On average, equities research analysts predict that Cross Country Healthcare, Inc. will post 0.06 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in shares of Cross Country Healthcare by 12.3% in the third quarter. Vanguard Group Inc. now owns 2,393,553 shares of the business services provider’s stock valued at $20,896,000 after purchasing an additional 262,049 shares during the last quarter. Arizona State Retirement System boosted its position in Cross Country Healthcare by 6.0% during the fourth quarter. Arizona State Retirement System now owns 55,826 shares of the business services provider’s stock worth $409,000 after acquiring an additional 3,175 shares during the last quarter. Crossmark Global Holdings Inc. boosted its position in Cross Country Healthcare by 99.3% during the fourth quarter. Crossmark Global Holdings Inc. now owns 30,910 shares of the business services provider’s stock worth $227,000 after acquiring an additional 15,400 shares during the last quarter. Rhumbline Advisers boosted its position in Cross Country Healthcare by 20.3% during the fourth quarter. Rhumbline Advisers now owns 105,960 shares of the business services provider’s stock worth $777,000 after acquiring an additional 17,899 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund acquired a new stake in Cross Country Healthcare during the fourth quarter worth approximately $101,000. 93.66% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages recently issued reports on CCRN. BidaskClub upgraded shares of Cross Country Healthcare from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 4th. Barrington Research set a $10.00 target price on shares of Cross Country Healthcare and gave the stock a “buy” rating in a research report on Monday, May 20th. ValuEngine raised shares of Cross Country Healthcare from a “sell” rating to a “hold” rating in a research note on Monday, April 1st. Finally, Zacks Investment Research raised shares of Cross Country Healthcare from a “strong sell” rating to a “hold” rating in a research note on Friday, May 3rd. Eight analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $9.80.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by Zolmax and is the property of of Zolmax. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://zolmax.com/investing/cross-country-healthcare-inc-nasdaqccrn-ceo-acquires-66640-00-in-stock/3116964.html.

Cross Country Healthcare Company Profile

Cross Country Healthcare, Inc provides healthcare staffing, recruiting, and workforce solutions in the United States. The company operates in three segments: Nurse and Allied Staffing, Physician Staffing, and Other Human Capital Management Services. The Nurse and Allied Staffing segment offers traditional staffing, including temporary and permanent placement of travel nurses and allied professionals, branch-based local nurses, and allied staffing; short-term staffing of registered nurses, licensed practical nurses, certified nurse assistants, practitioners, pharmacists, and other allied professionals on per diem and short-term assignments; and travel allied professionals on long-term contract assignments.

Read More: Price-Sales Ratio

Insider Buying and Selling by Quarter for Cross Country Healthcare (NASDAQ:CCRN)

Receive News & Ratings for Cross Country Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cross Country Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

KeyCorp Initiates Coverage on AppFolio
KeyCorp Initiates Coverage on AppFolio
Wolfgang Helmut Leoni Buys 410 Shares of Central and Eastern Europe Fund Inc  Stock
Wolfgang Helmut Leoni Buys 410 Shares of Central and Eastern Europe Fund Inc Stock
Raymond James Raises Amedisys  Price Target to $144.00
Raymond James Raises Amedisys Price Target to $144.00
Omeros’  Neutral Rating Reaffirmed at Wedbush
Omeros’ Neutral Rating Reaffirmed at Wedbush
Jefferies Financial Group Begins Coverage on Akero Therapeutics
Jefferies Financial Group Begins Coverage on Akero Therapeutics
Canaccord Genuity Begins Coverage on Slack
Canaccord Genuity Begins Coverage on Slack


 
© 2006-2019 Zolmax.